Answers are grounded in this paper and cite their sources.
Coronavirus pandemics such as Spanish influenza, severe acute respiratory syndrome-coronavirus (SARS-CoV), middle east respiratory syndrome-coronavirus (MERS-CoV) and severe acute respiratory syndrome-coronavirus (SARS-CoV-2) have displayed high incidence and mortality rates prompting the need for repurposing of drugs, vaccine development and the investigation of medicinal plants. Research on previous coronaviruses has served as the foundation for COVID-19 (arising from SARS-CoV-2) research. Various medicinal plants such as Glycyrrhiza glabra, Ginkgo biloba, Curcuma longa and Artemisia annua have displayed favorable results against SARS-CoV-2. Medicinal plants as well as bioactive compounds derived from medicinal plants have been investigated in clinical trials to elucidate the effect on SARS-CoV-2. Several clinical trials evaluate the effect of the medicinal plant and bioactive compounds derived thereof on symptoms arising due to SARS-CoV-2 thus, the main aim of this review article is to highlight the gap in the investigation of the effect of medicinal plants and bioactive compounds on the specific mechanisms of COVID-19 in clinical trials. The review also highlights challenges pertaining to the standardization and quality control of medicinal plants as well as bioactive compounds derived from medicinal plants which may impede the feasibility of using medicinal plants in the clinical regimen for COVID-19 or future coronavirus pandemics.
No takes yet. Share an insight, caveat, or question.
Alston et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: